The All India Drug Action Network (AIDAN) has urged the DCGI to reconsider the recommendations of the SEC in granting the REU approval to COVAXIN. The AIDAN has said it is shocked to learn about the recommendation to grant REU approval to Bharat Biotech's COVAXIN in "clinical trial mode" and "specially in the context of infection by mutant strains".from IndiaTV: Google News Feed https://ift.tt/3o8d5Y4
Post a Comment